Cost-Effective Use of Antiemetics

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 4, 1998, Pages 38-42

  Grunberg, Steven M ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT CARE; QUALITY OF LIFE; REVIEW; VOMITING;

ANTIEMETICS; COST-BENEFIT ANALYSIS; HUMANS; PILOT PROJECTS; SEROTONIN ANTAGONISTS; VOMITING, ANTICIPATORY;

EID: 0031979929     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Coates A, Abraham S, Kaye SB, et al: On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208, 1983.
2. Gralla RJ, Itri LM, Pisko SE, et al: Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905-909, 1981
3. Grunberg SM, Akerley WL, Krailo MD, et al: Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest 4:379-385, 1986.
4. Many M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine: (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis N Engl J Med 322:816-821, 1990.
5. Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991.
6. Gralla RJ, Popovic W, Strupp J, et al: Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin? Results of a 1054 patient randomized study of oral granisetron versus IV ondansetron (abstract). Proc Am Soc Clin Oncol 16:178a, 1997.
7. Perez EA, Chawla SP, Kaywin PK, et al: Efficacy and safety of oral granisetron versus IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting (abstract). Proc Am Soc Clin Oncol 16:149a, 1997
8. DiPiro CV, Sanal SM, Harkness KT, et al: The antiemetic efficacy of intravenous ondansetron at conventional versus low dose in women with early stage breast cancer (abstract). Proc Am Soc Clin Oncol 15:1752a, 1996.
9. Grunberg SM. Antiemetic drugs: Essential pharmacology, in Tonato M (ed): Antiemetics in the Supportive Care of Cancer Patients, pp 25-33. Berlin, Springer, 1996.
10. Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and seventy of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384, 1985.
11. Kris MG, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114, 1989.
12. The Italian Group for Antiemetic Research: Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124-130, 1997.
13. Herrstedt J, Sigsgaard T, Handberg J, et al: Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 15:1690-1696, 1997.
14. Herrstedt J, Sigsgaard T, Boesgaard M, et al: Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328:1076-1080, 1993.
15. Cunningham D, Gore M, Davidson N, et al: The real costs of emesis - an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancel. Eur J Cancer 29A.303-306, 1993.
16. Ballatori E, Roila F, Berto P, et al: Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: A hospital perspective from Italy. Pharmacoeconomics 5:227-237, 1994.
17. Cox F, Hirsch J: Ondansetron - a cost-effective advance in antiemetic therapy. Oncology 50:186-190, 1993.
18. Grunberg SM, Boutin N, Ireland A, et al: Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4.435-439, 1996.